Richard Carvajal on Immunotherapy Dosing


Richard Carvajal, MD, discusses how to make decisions regarding the dosing limits of immunotherapy agents.

Richard Carvajal, MD, from Columbia University Medical Center discusses deciding on dosing limits for immunotherapy treatments.

The proper dosing for immunotherapy efficacy is unclear. For chemotherapy, the patients can often be pushed to toxicity. However, with immunotherapies and targeted therapies, there are responses seen after 1 or 2 doses. There are also durable responses in some patients if treatment is stopped.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
© 2024 MJH Life Sciences

All rights reserved.